A Dose Escalation Study of R115777 (Zarnestra) Combined With Velcade (PS-341) in Patients With Relapsed Multiple Myeloma
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Tipifarnib (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 07 Oct 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 26 Mar 2009 Additional lead trial centres and lead investigator identified as reported by ClinicalTrials.gov.
- 24 Mar 2009 Planned number of patients changed from 52 to 64 as reported by ClinicalTrials.gov.